Your browser doesn't support javascript.
loading
Targeting TRIM29 As a Negative Regulator of CAR-NK Cell Effector Function to Improve Antitumor Efficacy of These Cells: A Perspective.
Saleh, Zahra; Noroozi, Maryam; Eshkevar Vakili, Mahsa; Kabelitz, Dieter; Nasrolahi, Hamid; Kalantar, Kurosh.
Afiliação
  • Saleh Z; Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Noroozi M; Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Eshkevar Vakili M; Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Kabelitz D; Institute of Immunology, Christian-Albrechts University of Kiel and University Hospital Schleswig, Holstein Campus Kiel, 24105, Kiel, Germany.
  • Nasrolahi H; Radio-Oncology department, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Kalantar K; Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Curr Mol Med ; 2023 May 10.
Article em En | MEDLINE | ID: mdl-37218209
ABSTRACT
Natural killer (NK) cells are among the most important cells in innate immune defense. In contrast to T cells, the effector function of NK cells does not require prior stimulation and is not MHC restricted. Therefore, chimeric antigen receptor (CAR)-NK cells are superior to CAR-T cells. The complexity of the tumor microenvironment (TME) makes it necessary to explore various pathways involved in NK cell negative regulation. CAR-NK cell effector function can be improved by inhibiting the negative regulatory mechanisms. In this respect, the E3 ubiquitin ligase tripartite motif containing 29 (TRIM29) is known to be involved in reducing NK cell cytotoxicity and cytokine production. Also, targeting TRIM29 may enhance the antitumor efficacy of CAR-NK cells. The present study discusses the negative effects of TRIM29 on NK cell activity and genomic deletion or suppression of the expression of TRIM29 as a novel approach to optimize CAR-NK cell-based immunotherapy.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Curr Mol Med Assunto da revista: BIOLOGIA MOLECULAR Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Irã

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Curr Mol Med Assunto da revista: BIOLOGIA MOLECULAR Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Irã